Skip to Main Content

Patrick A. Kenney, MD

Associate Professor of Urology; Medical Director, Smilow Cancer Hospital Care Center at Greenwich Hospital

Research Summary

Dr. Kenney's research focuses on clinical trials in the neoadjuvant and adjuvant settings for locally and regionally advanced urologic cancers, as well as for treatment-resistant cancers. In addition, Dr. Kenney researches provision of care and surgical quality and safety.

Coauthors

Research Interests

Carcinoma, Renal Cell; Health Services; Nephrectomy; Quality of Health Care; Health Care Quality, Access, and Evaluation; Neoadjuvant Therapy; Cytoreduction Surgical Procedures

Selected Publications

  • Urology Practice Acquisitions by Private Equity Firms from 2011–2021Nie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Urology Practice Acquisitions by Private Equity Firms from 2011–2021 Urology Practice 2021, 9: 17-24. DOI: 10.1097/upj.0000000000000269.
  • Reply by AuthorsNie J, Demkowicz P, Hsiang W, Umer W, Chen E, McMahon G, Kenney P, Breyer B, Parikh R, Leapman M. Reply by Authors Urology Practice 2021, 9: 24-24. DOI: 10.1097/upj.0000000000000269.02.
  • PD38-10 AN INITIATIVE TO REDUCE DOOR TO INCISION TIME FOR PATIENTS WITH TESTICULAR TORSIONNguyen J, Buck M, Abello A, Casilla - Lennon M, Leapman M, Hittelman A, Teitelbaum J, Emerson B, Cavallo J, Kenney P, Lambert S. PD38-10 AN INITIATIVE TO REDUCE DOOR TO INCISION TIME FOR PATIENTS WITH TESTICULAR TORSION Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002048.10.
  • PD38-07 ANTIBIOTIC PROPHYLAXIS PRIOR TO OUTPATIENT UROLOGIC PROCEDURES: OUTCOMES FROM A DEPARTMENT-WIDE QUALITY IMPROVEMENT PROJECTBuck M, Nguyen J, Abello A, Leapman M, Cavallo J, Kenney P. PD38-07 ANTIBIOTIC PROPHYLAXIS PRIOR TO OUTPATIENT UROLOGIC PROCEDURES: OUTCOMES FROM A DEPARTMENT-WIDE QUALITY IMPROVEMENT PROJECT Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002048.07.
  • Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act.Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.
  • Accessibility of Telehealth services for cancer care at cancer hospital in the United States.Marks V, Hsiang W, Nie J, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Accessibility of Telehealth services for cancer care at cancer hospital in the United States. Journal Of Clinical Oncology 2021, 39: 6535-6535. DOI: 10.1200/jco.2021.39.15_suppl.6535.
  • Access to cancer care for Medicaid patients at cancer hospitals in the United States.Marks V, Hsiang W, Nie J, Buck M, Demkowicz P, Umer W, Haleem A, Galal B, Pak I, Kim D, Kenney P, Leapman M. Access to cancer care for Medicaid patients at cancer hospitals in the United States. Journal Of Clinical Oncology 2021, 39: 6548-6548. DOI: 10.1200/jco.2021.39.15_suppl.6548.
  • PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancerAbello A, Renzulli J, Park H, Leapman M, Kenney P. PT414 Similar survival outcomes among chemoradiation and neoadjuvant chemotherapy with radical cystectomy for small cell bladder cancer European Urology Open Science 2020, 19: e2283. DOI: 10.1016/s2666-1683(20)34148-3.
  • PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomyAbello A, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. PT417 National variation in lymph node dissection and pathological yield at the time of radical cystectomy European Urology Open Science 2020, 19: e2286. DOI: 10.1016/s2666-1683(20)34151-3.
  • Analysis of Cost Variation in Endourological Procedures throughout the United States Using a National DatabaseAbello A, Goland-Van Ryn M, Kenney P, Singh D, Motamedinia P. Analysis of Cost Variation in Endourological Procedures throughout the United States Using a National Database Urology Practice 2020, 7: 174-181. DOI: 10.1097/upj.0000000000000080.
  • MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMYAbello* A, Nawaf C, Brito J, Sprenkle P, Kenney P, Renzulli J, Leapman M. MP61-12 NATIONAL VARIATION IN LYMPH NODE DISSECTION AND PATHOLOGICAL YIELD AT THE TIME OF RADICAL CYSTECTOMY Investigative Urology 2020, 203: e939-e940. DOI: 10.1097/ju.0000000000000936.012.
  • MP68-05 CLINICAL OUTCOMES OF LOW-STAGE SARCOMATOID RENAL CELL CARCINOMAAbello* A, Nawaf C, Leapman M, Kenney P. MP68-05 CLINICAL OUTCOMES OF LOW-STAGE SARCOMATOID RENAL CELL CARCINOMA Investigative Urology 2020, 203: e1036. DOI: 10.1097/ju.0000000000000948.05.
  • PD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCERAbello* A, Nawaf C, Renzulli J, Park H, Leapman M, Kenney P. PD55-02 SIMILAR SURVIVAL OUTCOMES AMONG CHEMORADIATION AND NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY FOR SMALL CELL BLADDER CANCER Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000965.02.
  • PD05-06 CREATION OF EPIC-BASED DASHBOARD TO TRACK AND REPORT PERIOPERATIVE OUTCOMES AND SURGEON PERFORMANCEJavier-DesLoges* J, Abello A, Kenney P. PD05-06 CREATION OF EPIC-BASED DASHBOARD TO TRACK AND REPORT PERIOPERATIVE OUTCOMES AND SURGEON PERFORMANCE Investigative Urology 2020, 203 DOI: 10.1097/ju.0000000000000825.06.
  • Open Partial NephrectomyCasilla-Lennon M, Kenney P, Wszolek M, Libertino J. Open Partial Nephrectomy 2019, 221-242. DOI: 10.1007/978-3-030-24378-4_13.
  • Unified Approaches to Surgery and Systemic Therapy for Renal Cell CarcinomaAbello A, Kenney P. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma 2019, 411-435. DOI: 10.1007/978-3-030-24378-4_24.
  • PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCERAbello* A, Sprenkle P, Kenney P, Leapman M. PD17-02 CLINICAL RISK BASED ASSOCIATIONS OF LYMPH NODE DISSECTION AND DETECTION YIELD AMONG MEN TREATED WITH RADICAL PROSTATECTOMY FOR PROSTATE CANCER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000555562.32224.0f.
  • PD58-05 UROLOGIC MALIGNANCIES: A COMPARISON OF OUTCOMES AFTER INDEX SURGERY BETWEEN ACADEMIC AND COMMUNITY HOSPITALSSyed* J, Abello A, Javier-DesLoges J, Leapman M, Kenney P. PD58-05 UROLOGIC MALIGNANCIES: A COMPARISON OF OUTCOMES AFTER INDEX SURGERY BETWEEN ACADEMIC AND COMMUNITY HOSPITALS Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557173.74355.7e.
  • PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDERJavier-DesLoges* J, Abello A, Syed J, Sprenkle P, Hurwitz M, Kenney P, Leapman M. PD66-04 NATIONAL TRENDS AND PATHOLOGIC OUTCOMES OF NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS WITH MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA OF THE BLADDER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557466.16539.88.
  • MP29-19 CHASING THE PACK: ASSOCIATION BETWEEN UROLOGY HOSPITAL RANKINGS AND SURGICAL OUTCOMEAbello* A, Syed J, Leapman M, Kenney P. MP29-19 CHASING THE PACK: ASSOCIATION BETWEEN UROLOGY HOSPITAL RANKINGS AND SURGICAL OUTCOME Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557554.82490.aa.
  • Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy.Abello A, Kenney P, Leapman M. Clinical risk-based associations of lymph node dissection and detection of metastasis among men treated with radical prostatectomy. Journal Of Clinical Oncology 2019, 37: 284-284. DOI: 10.1200/jco.2019.37.7_suppl.284.
  • Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals.Syed J, Abello A, Javier-Desloges J, Leapman M, Kenney P. Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals. Journal Of Clinical Oncology 2019, 37: 489-489. DOI: 10.1200/jco.2019.37.7_suppl.489.
  • Associations of rurality and disease outcomes in urologic malignancies.Abello A, Casilla-Lennon M, Kenney P, Leapman M. Associations of rurality and disease outcomes in urologic malignancies. Journal Of Clinical Oncology 2019, 37: 661-661. DOI: 10.1200/jco.2019.37.7_suppl.661.
  • MP80-02 LEVERAGING STRUCTURED DATA IN AN ENTERPRISE-WIDE ELECTRONIC HEALTH RECORD TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE URINARY RETENTIONJavier-DesLoges J, Amirkhiz K, Su J, Kenney P, Advani S, Hittelman A, Leapman M. MP80-02 LEVERAGING STRUCTURED DATA IN AN ENTERPRISE-WIDE ELECTRONIC HEALTH RECORD TO IDENTIFY RISK FACTORS FOR POSTOPERATIVE URINARY RETENTION Investigative Urology 2018, 199: e1089. DOI: 10.1016/j.juro.2018.02.2690.
  • MP50-13 NOVEL USE OF THE EPIC ELECTRONIC MEDICAL RECORD PLATFORM TO IDENTIFY LOST URETERAL STENTSJavier-Desloges J, Johnson K, Bryson C, Olszyk R, Kenney P, Motamedinia P. MP50-13 NOVEL USE OF THE EPIC ELECTRONIC MEDICAL RECORD PLATFORM TO IDENTIFY LOST URETERAL STENTS Investigative Urology 2018, 199: e680. DOI: 10.1016/j.juro.2018.02.1624.
  • PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY?Keskin S, Petros F, Yu K, Aboshady Y, Borregales L, Kenney P, Matin S, Karam J, Wood C. PD04-09 SHOULD PATIENTS WITH METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA UNDERGO CYTOREDUCTIVE NEPHRECTOMY? Investigative Urology 2017, 197: e65-e66. DOI: 10.1016/j.juro.2017.02.228.
  • MP86-17 THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRARobins D, Small A, Amin M, Bochner B, Chang S, Choueiri T, Efstathiou J, Gospodarowicz M, Hansel D, Kenney P, Konety B, Landman J, Lee C, Leibovich B, Plimack E, Reuter V, Rini B, Sridhar S, Stadler W, Tickoo S, Vikram R, Zhou M, McKiernan J. MP86-17 THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA Investigative Urology 2017, 197: e1163. DOI: 10.1016/j.juro.2017.02.2700.
  • KidneyRini B, McKiernan J, Chang S, Choueiri T, Kenney P, Landman J, Leibovich B, Tickoo S, Vikram R, Zhou M, Stadler W. Kidney 2016, 747-756. DOI: 10.1007/978-3-319-40618-3_60.
  • Predicting pulmonary metastases among patients with indeterminate pulmonary nodules with renal cell carcinoma.Adibi M, Kenney P, Thomas A, Devine C, Karam J, Wood C. Predicting pulmonary metastases among patients with indeterminate pulmonary nodules with renal cell carcinoma. Journal Of Clinical Oncology 2015, 33: 505-505. DOI: 10.1200/jco.2015.33.7_suppl.505.
  • 1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection?Babaian K, Kenney P, Karam J, Wood C. 1042 Predictors of occult lymph node metastases in patients with locally advanced renal cell carcinoma: Who should have a lymph node dissection? European Urology Open Science 2014, 13: e1042. DOI: 10.1016/s1569-9056(14)61024-1.
  • MP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION?Babaian K, Kenney P, Kim D, Qiao W, Karam J, Wood C. MP64-03 PREDICTORS OF OCCULT LYMPH NODE METASTASES IN PATIENTS WITH RENAL CELL CARCINOMA: WHO SHOULD UNDERGO A LYMPH NODE DISSECTION? Investigative Urology 2014, 191: e701. DOI: 10.1016/j.juro.2014.02.1920.
  • Unified Approaches to Surgery and Systemic Therapy for Renal Cell CarcinomaKenney P, Wood C. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma 2013, 155-177. DOI: 10.1007/978-1-4614-7236-0_10.
  • Open Partial NephrectomyKenney P, Wszolek M, Libertino J. Open Partial Nephrectomy 2013, 211-231. DOI: 10.1007/978-1-4614-7236-0_13.
  • 1906 PREOPERATIVE PULMONARY EMBOLISM DOES NOT PREDICT POOR POSTSURGICAL OUTCOMES IN RCC PATIENTS WITH VENOUS THROMBUSAbel E, Wood C, Eickstaedt N, Fang J, Kenney P, Bagrodia A, Ramirez D, Gayed B, Downs T, Youssef R, Odom C, Sagalowsky A, Margulis V. 1906 PREOPERATIVE PULMONARY EMBOLISM DOES NOT PREDICT POOR POSTSURGICAL OUTCOMES IN RCC PATIENTS WITH VENOUS THROMBUS Investigative Urology 2013, 189: e781. DOI: 10.1016/j.juro.2013.02.2325.
  • 1073 CLINICAL PREDICTORS FOR THE DEVELOPMENT OF PULMONARY METASTASES AMONG RCC PATIENTS WITH INDETERMINATE PULMONARY NODULESKenney P, Karam J, Levey R, Nogueras-Gonzalez G, Matin S, Tamboli P, Tannir N, Wood C. 1073 CLINICAL PREDICTORS FOR THE DEVELOPMENT OF PULMONARY METASTASES AMONG RCC PATIENTS WITH INDETERMINATE PULMONARY NODULES Investigative Urology 2013, 189: e440. DOI: 10.1016/j.juro.2013.02.662.
  • Outcomes of RCC patients with venous thrombus presenting with pulmonary embolism: A multicenter analysis of 782 consecutive patients.Abel E, Wood C, Kenney P, Eickstaedt N, Bagrodia A, Ramirez D, Gayed B, Youssef R, Odom C, Margulis V. Outcomes of RCC patients with venous thrombus presenting with pulmonary embolism: A multicenter analysis of 782 consecutive patients. Journal Of Clinical Oncology 2013, 31: 433-433. DOI: 10.1200/jco.2013.31.6_suppl.433.
  • 1802 DOES CYTOREDUCTIVE NEPHRECTOMY IMPROVE SURVIVAL IN NON-CLEAR CELL RENAL CELL CARCINOMA?Kenney P, Chapin B, Culp S, Richey S, González G, Tamboli P, Tannir N, Wood C. 1802 DOES CYTOREDUCTIVE NEPHRECTOMY IMPROVE SURVIVAL IN NON-CLEAR CELL RENAL CELL CARCINOMA? Investigative Urology 2012, 187: e727. DOI: 10.1016/j.juro.2012.02.1833.
  • Nodal disease in the setting of metastatic renal cell carcionoma: Can a lymph node dissection alter outcomes?Chapin B, Delacroix S, Kenney P, Nogueras Gonzalez G, Tamboli P, Jonasch E, Tannir N, Wood C. Nodal disease in the setting of metastatic renal cell carcionoma: Can a lymph node dissection alter outcomes? Journal Of Clinical Oncology 2012, 30: 386-386. DOI: 10.1200/jco.2012.30.5_suppl.386.
  • chapter 54 Contemporary Open Surgery of the KidneyKenney P, Wotkowicz C, Libertino J. chapter 54 Contemporary Open Surgery of the Kidney 2012, 1554-1627.e5. DOI: 10.1016/b978-1-4160-6911-9.00054-2.
  • 963 THE RENAL NEPHROMETRY SCORING SYSTEM IS PREDICTIVE OF PARTIAL NEPHRECTOMY COMPLEXITYKenney P, Kozinn S, Lebeis C, Lee Y, Libertino J, Moinzadeh A. 963 THE RENAL NEPHROMETRY SCORING SYSTEM IS PREDICTIVE OF PARTIAL NEPHRECTOMY COMPLEXITY Investigative Urology 2011, 185: e388-e389. DOI: 10.1016/j.juro.2011.02.931.
  • 1254 POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY FOR PT1 LOCALIZED RENAL CELL CARCINOMA: LOCAL RECURRENCE AND RCC-SPECIFIC SURVIVALFaust W, Kenney P, Moinzadeh A, Libertino J. 1254 POSITIVE SURGICAL MARGINS AFTER PARTIAL NEPHRECTOMY FOR PT1 LOCALIZED RENAL CELL CARCINOMA: LOCAL RECURRENCE AND RCC-SPECIFIC SURVIVAL Investigative Urology 2011, 185: e502. DOI: 10.1016/j.juro.2011.02.939.
  • 966 COMPARISON OF HILAR CLAMPING AND NON-HILAR CLAMPING PARTIAL NEPHRECTOMY FOR TUMORS INVOLVING A SOLITARY KIDNEYWszolek M, Kenney P, Lee Y, Libertino J. 966 COMPARISON OF HILAR CLAMPING AND NON-HILAR CLAMPING PARTIAL NEPHRECTOMY FOR TUMORS INVOLVING A SOLITARY KIDNEY Investigative Urology 2011, 185: e389-e390. DOI: 10.1016/j.juro.2011.02.934.
  • 520 INTEROBSERVER RELIABILITY OF THE RENAL NEPHROMETRY SCORING SYSTEMKenney P, Kozinn S, Wszolek M, Behr S, Lee Y, Libertino J, Moinzadeh A. 520 INTEROBSERVER RELIABILITY OF THE RENAL NEPHROMETRY SCORING SYSTEM Investigative Urology 2010, 183: e205-e206. DOI: 10.1016/j.juro.2010.02.596.
  • 1141 NOVEL ZEB1 EXPRESSION LINKED TO ALTERED MICRORNA EXPRESSION PROFILES IN BLADDER TUMOR PROGRESSIONKenney P, Harty N, Wszolek M, Rieger-Christ K, Neto B, Gould J, Zeheb R, Loda M, Libertino J, Summerhayes I. 1141 NOVEL ZEB1 EXPRESSION LINKED TO ALTERED MICRORNA EXPRESSION PROFILES IN BLADDER TUMOR PROGRESSION Investigative Urology 2010, 183: e441-e442. DOI: 10.1016/j.juro.2010.02.640.
  • Laparoscopic Partial NephrectomyKenney P, Gould J, Tsai S, Canes D. Laparoscopic Partial Nephrectomy 2010, 187-196. DOI: 10.1007/978-1-84882-178-1_22.
  • VALIDATION OF THE DV-TRAINER ®, A NOVEL VIRTUAL REALITY SIMULATOR FOR ROBOTIC SURGERYKenney P, Wszolek M, Gould J, Libertino J, Moinzadeh A. VALIDATION OF THE DV-TRAINER ®, A NOVEL VIRTUAL REALITY SIMULATOR FOR ROBOTIC SURGERY Investigative Urology 2009, 181: 792. DOI: 10.1016/s0022-5347(09)62206-0.
  • IDENTIFICATION OF MODULATORS OF TUMOR AND INVASIVE SUPPRESSOR GENES BY DIFFERENT CLASSES OF HISTONE DEACETYLASE INHIBITORS USING REVERSE PHASE PROTEIN ARRAYSGould J, Kenney P, Wszolek M, Rieger-Christ K, Neto B, Holway A, Spurrier B, Austin J, Libertino J, Summerhayes I. IDENTIFICATION OF MODULATORS OF TUMOR AND INVASIVE SUPPRESSOR GENES BY DIFFERENT CLASSES OF HISTONE DEACETYLASE INHIBITORS USING REVERSE PHASE PROTEIN ARRAYS Investigative Urology 2009, 181: 346. DOI: 10.1016/s0022-5347(09)60985-x.
  • A MICRORNA EXPRESSION PROFILE INVOLVED IN THE INVASIVE BLADDER TUMOR PHENOTYPEWszolek M, Gould J, Kenney P, Rieger-Christ K, Neto B, LaVoie A, Libertino J, Summerhayes I. A MICRORNA EXPRESSION PROFILE INVOLVED IN THE INVASIVE BLADDER TUMOR PHENOTYPE Investigative Urology 2009, 181: 347. DOI: 10.1016/s0022-5347(09)60987-3.

Clinical Trials